Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
5-day change
1st Jan Change
45.03
USD
-0.86%
+6.08%
-1.57%
Presentation Operator MessageOperator (Operator)Hello, and thank you for joining us to discuss...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
May. 14
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 14
CI
Belite Bio's Q1 Loss Narrows
May. 14
MT
Transcript : Belite Bio, Inc - Special Call
May. 13
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May. 06
CI
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares
Apr. 26
MT
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan
Mar. 22
MT
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Mar. 22
CI
ADRs End Higher, ATRenew Inc. Climbs 26.9%
Mar. 12
DJ
Transcript : Belite Bio, Inc, Q4 2023 Earnings Call, Mar 12, 2024
Mar. 12
Belite Bio's Q4 Loss Narrows
Mar. 12
MT
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 12
CI
Belite Bio Gets Clearance to Launch Tinlarebant Phase 3 Trial for Eye Disease in China
Dec. 27
MT
Maxim Starts Coverage on Belite Bio with Buy Rating, $60 Price Target
Dec. 14
MT
Transcript : Belite Bio, Inc, Q3 2023 Earnings Call, Nov 14, 2023
Nov. 14
Belite Bio, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
Belite Bio's Q3 Loss Widens
Nov. 14
MT
Transcript : Belite Bio, Inc Presents at DbVIC - Deutsche Bank Depositary Receipts Virtual Investor Conference, Nov-08-2023 11:00 AM
Nov. 08
HC Wainwright Raises Price Target on Belite Bio to $59 From $55, Maintains Buy Rating
Nov. 06
MT
Belite Bio, Inc. Presents Results from a 24-Month, Phase 2 Study of Tinlarebant in Childhood-Onset Stargardt Disease at the AAO Annual Meeting
Nov. 06
CI
ADRs Dip; Voxeljet AG Declines 24%
23-08-18
DJ
Transcript : Belite Bio, Inc, Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Belite Bio, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Cantor Fitzgerald Initiates Belite Bio at Overweight Rating With $43 Price Target
23-07-28
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
More about the company
Last Close Price
45.03
USD
Average target price
56.5
USD
Spread / Average Target
+25.47%
Consensus
1st Jan change
Capi.
-1.57% 1.31B +64.23% 62.59B -2.31% 41.18B +44.36% 40.29B -8.29% 27.9B +11.97% 26.21B -21.16% 19.09B +7.54% 13.08B +27.17% 12.05B +25.72% 12.26B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1